- English (USA)
- English (UK)
- English (India)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
SBT Ultrasonic Technology Co Ltd (688392)
SBT Ultrasonic Technology Co Ltd stock price live, this page displays SS 688392 stock exchange data. View the 688392 premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the SBT Ultrasonic Technology Co Ltd real time stock price chart below.
What Is the SBT Ultrasonic Technology Co Ltd Stock Price Today?
The SBT Ultrasonic Technology Co Ltd stock price today is 184.91.
What Is the Stock Symbol for SBT Ultrasonic Technology Co Ltd?
The stock symbol for SBT Ultrasonic Technology Co Ltd is "688392."
What Stock Exchange Does SBT Ultrasonic Technology Co Ltd Trade On?
SBT Ultrasonic Technology Co Ltd is listed and trades on the Shanghai stock exchange.
Is SBT Ultrasonic Technology Co Ltd a Good Stock to Buy?
Determining whether SBT Ultrasonic Technology Co Ltd—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the 688392 quote. (ISIN: CNE100005P15)
What Is the SBT Ultrasonic Technology Co Ltd Stock Price Today?
The SBT Ultrasonic Technology Co Ltd stock price today is 184.91.
What Is the Stock Symbol for SBT Ultrasonic Technology Co Ltd?
The stock symbol for SBT Ultrasonic Technology Co Ltd is "688392."
What Stock Exchange Does SBT Ultrasonic Technology Co Ltd Trade On?
SBT Ultrasonic Technology Co Ltd is listed and trades on the Shanghai stock exchange.
Is SBT Ultrasonic Technology Co Ltd a Good Stock to Buy?
Determining whether SBT Ultrasonic Technology Co Ltd—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the 688392 quote. (ISIN: CNE100005P15)
Shanghai
Currency in CNY
184.91
-2.39(-1.28%)
Closed·
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
177.03
185.58
52 wk Range
74.90
248.00
688392 is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
177.03185.58
52 wk Range
74.90248.00
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Book Value / Share
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Book Value / Share
688392 Scorecard
Company’s Health
Assesses a company's financial position by analyzing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceAnalysts Sentiment
Strong Buy
Price Target
35.23
Downside
-80.95%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Trading at a low P/E ratio relative to near-term earnings growth
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Sell
Technical Indicators
Strong Sell
Moving Averages
Neutral
Analyst Ratings
4 Buy
0 Hold
0 Sell
Ratings:
4 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 35.23
(-80.95% Downside)
Earnings
Latest Release
Aug 29, 2026
EPS / Forecast
0.44 / 0.44
Revenue / Forecast
235.92M / 235.92M
Compare 688392 to Peers and Sector
Metrics to compare | 688392 | Sector Sector - Average of metrics from a broad group of related Industrials sector companies | Relationship Relationship688392PeersSector | |
|---|---|---|---|---|
P/E Ratio | 28.0x | −2.3x | −0.4x | |
PEG Ratio | 0.37 | 0.05 | 0.00 | |
Price/Book | 3.4x | 5.0x | 2.6x | |
Price / LTM Sales | 9.3x | 12.4x | 3.1x | |
Upside (Analyst Target) | −81.6% | 46.7% | 47.7% | |
Fair Value Upside | Unlock | 5.1% | 6.5% | Unlock |
InnoCare Pharma Limited, a biopharmaceutical company, engages in discovering, developing, and commercializing drugs for the treatment of cancer and autoimmune diseases in China. The company develops Orelabrutinib, an BTK inhibitor to treat patients with relapsed and/or refractory (r/r) chronic lymphocytic leukemia, r/r mantle cell lymphoma, r/r Waldenstrom’s macroglobulinemia, r/r marginal zone lymphoma, r/r diffuse large B-cell lymphoma (DLBCL)- MCD, r/r central nervous system lymphoma, combo w/MIL-62, systemic lupus erythematosus, immune thrombocytopenia purpura, multiple sclerosis, and neuromyelitis optica spectrum disorder. It also developing ICP-B02 to treat CD20+B-cell malignancies; ICP-B05 to treat hemato-oncology; ICP-248 to treat chronic lymphocytic leukemia; ICP-332 to treat atopic dermatitis; ICP-488 to treat psoriasis; ICP-538 to treat autoimmune diseases; zurletrectinib (ICP-723) to treat neurotrophic tyrosine receptor kinase fusion positive cancers; ICP-189 to treat non-small cell lung cancer; and ICP-B05 to treat solid tumor. InnoCare Pharma Limited was incorporated in 2015 and is headquartered in Beijing, China.
Ownership
Ownership Overview
Top Holders
FAQ
What Is the SBT Ultrasonic Tech (688392) Stock Price Today?
The SBT Ultrasonic Tech stock price today is 184.91 CNY.
What Stock Exchange Does SBT Ultrasonic Tech Trade On?
SBT Ultrasonic Tech is listed and trades on the Shanghai Stock Exchange.
What Is the Stock Symbol for SBT Ultrasonic Tech?
The stock symbol for SBT Ultrasonic Tech is "688392."
What Is the SBT Ultrasonic Tech Market Cap?
As of today, SBT Ultrasonic Tech market cap is 25.74B CNY.
What Is SBT Ultrasonic Tech's Earnings Per Share (TTM)?
The SBT Ultrasonic Tech EPS (TTM) is 0.51.
When Is the Next SBT Ultrasonic Tech Earnings Date?
SBT Ultrasonic Tech will release its next earnings report on Oct 26, 2026.
From a Technical Analysis Perspective, Is 688392 a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Buy.
How Many Times Has SBT Ultrasonic Tech Stock Split?
SBT Ultrasonic Tech has split 0 times.
How Many Employees Does SBT Ultrasonic Tech Have?
SBT Ultrasonic Tech has 1388 employees.
What is the current trading status of SBT Ultrasonic Tech (688392)?
As of Aug 31, 2026, SBT Ultrasonic Tech (688392) is trading at a price of 184.91 CNY, with a previous close of 187.30 CNY. The stock has fluctuated within a day range of 177.03 CNY to 185.58 CNY, while its 52-week range spans from 74.90 CNY to 248.00 CNY.
What Is SBT Ultrasonic Tech (688392) Price Target According to Analysts?
The average 12-month price target for SBT Ultrasonic Tech is 35.23 CNY, with a high estimate of 37.93 CNY and a low estimate of 34 CNY. 4 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an -80.95% Downside potential.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.